Niagen Bioscience Inc (NASDAQ:NAGE - Get Free Report)'s stock price shot up 8.2% on Monday . The stock traded as high as $11.79 and last traded at $11.71. 1,378,641 shares traded hands during trading, an increase of 63% from the average session volume of 846,135 shares. The stock had previously closed at $10.82.
Analyst Upgrades and Downgrades
Separately, Canaccord Genuity Group started coverage on Niagen Bioscience in a research report on Tuesday, May 27th. They issued a "buy" rating and a $13.00 price objective for the company.
Get Our Latest Research Report on Niagen Bioscience
Niagen Bioscience Stock Up 0.1%
The business has a fifty day moving average price of $8.37. The firm has a market cap of $923.97 million, a PE ratio of 69.00 and a beta of 1.94.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Further Reading
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
